Anavex Life Sciences (AVXL) vs Protara Therapeutics (TARA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Protara Therapeutics (TARA) has outperformed Anavex Life Sciences (AVXL) over the past year, losing 50.9% versus a loss of 84.3%. Over five years, TARA leads with a -59.7% price change compared with -91.5% for AVXL. Protara Therapeutics is the larger company by market cap ($162.8 million vs $138.1 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVXL | TARA |
|---|---|---|
| Share price | $1.49 | $2.76 |
| Market cap | $138.12M | $162.81M |
| 1-day change | -3.25% | +3.96% |
| YTD return | -58.15% | -48.31% |
| 1-year return | -84.35% | -50.89% |
| 5-year return | -91.50% | -59.72% |
| EPS (TTM) | $-0.14 | $-1.41 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.50 | $7.82 |
| 52-week low | $1.44 | $2.51 |
| Distance from 52-week high | -84.32% | -64.77% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | — | +833.21% |
| Average volume | 983.35K | 814.80K |
| Shares outstanding | 92.70M | 59.10M |
| Employees | 34 | 46 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TARA has outperformed AVXL by 33.5 percentage points over the past year.
About Anavex Life Sciences
AVXL stock →Anavex Life Sciences Corp. operates as a biopharmaceutical company.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 34 employees
About Protara Therapeutics
TARA stock →Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 46 employees
AVXL vs TARA FAQ
Which is bigger, Anavex Life Sciences or Protara Therapeutics?
Protara Therapeutics (TARA) is larger, with a market capitalization of $162.81M compared with $138.12M for Anavex Life Sciences (AVXL).
Which stock has performed better over the past year, AVXL or TARA?
TARA returned -50.89% over the past 12 months, compared with -84.35% for AVXL (price return, excluding dividends). Past performance does not predict future results.
Are Anavex Life Sciences and Protara Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.